Morrison Jodie Pope — SEC Form 4 filings
SEC reporting owner CIK 1618247. 11 Form 4 filings on record with FilingPulse; latest filed 2026-08-27.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-03-27 to 2026-08-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 52,741 shares, $304,478 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 9,845 shares @ $16.56 ($163,033) in Q32 Bio Inc., filed 2026-08-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Q32 Bio Inc. (QTTB) | CEO, Director | 8 | — | 4 legs · 52,741 sh · $304,478 | 12 |
| Verve Therapeutics, Inc. (VERV) | Director | 3 | — | — | 4 |
Form 4 filings — Morrison Jodie Pope
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | Q32 Bio Inc. (QTTB) | Sale (S): 9,845 @ $16.56 | EDGAR |
| 2026-07-20 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-03-20 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-02-27 | 4 | Q32 Bio Inc. (QTTB) | Sale (S): 9,896 @ $4.51 | EDGAR |
| 2025-12-04 | 4 | Q32 Bio Inc. (QTTB) | Sale (S): 22,506 @ $3.46 | EDGAR |
| 2025-08-28 | 4 | Q32 Bio Inc. (QTTB) | Sale (S): 10,494 @ $1.80 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Disposition to issuer (D): 267,541 (derivative) · Disposition to issuer (D): 42,200 (derivative) | EDGAR |
| 2025-06-06 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 42,200 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 132,000 @ $0 · Disposition to issuer (D): 152,700 (derivative) @ $0 · Grant/award (A): 152,700 (derivative) @ $0 · Disposition to issuer (D): 152,700 (derivative) @ $0 · Grant/award (A): 152,700 (derivative) @ $0 · Disposition to issuer (D): 16,901 (derivative) @ $0 · +3 more | EDGAR |
| 2024-06-28 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 267,541 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 394,445 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1618247 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →